CSF3 and kidney disorder: Furthermore, there was no difference in the proportion of SLE patients with detectable serum G‐CSF concentrations between SLE patients with active (82.6%, 38/46) or inactive (84.9%, 129/152) renal disease (p = .71, Pearson's χ2 test), nor in the serum G‐CSF concentrations between SLE patients with active (median: 404.0 pg/ml, IQR: 115.4–990.8) or inactive (median: 371.4 pg/ml, IQR: 161.5–1350.2) renal disease (Figure 6B).